Limulus Amebocyte Lysate (LAL) Assay

The assay uses lysate from horseshoe crab amebocytes, whose clotting cascade is initiated by bacterial lipopolysaccharide: endotoxin activates Factor C, which activates Factor B, which activates a clotting enzyme that converts coagulogen into a gel. Three readouts exploit that cascade: gel-clot, read by eye against a lysate of stated sensitivity; turbidimetric, following the developing haze; and kinetic chromogenic, which substitutes a synthetic substrate for coagulogen and measures the rate at which the enzyme releases a chromophore.

Two controls decide whether a result means anything. Every sample must pass an inhibition and enhancement test, in which a known quantity of endotoxin is spiked into the diluted sample and must be recovered within a defined window, because peptides, chelators, surfactants and extremes of pH all interfere with the cascade. The maximum valid dilution caps how far a sample may be diluted to escape that interference while still detecting the product's limit. Recombinant Factor C assays replace crab lysate with one cloned enzyme and are now in the pharmacopoeias.

The assay answers one question: is gram-negative endotoxin present above the limit. It does not detect gram-positive pyrogens, and beta-glucans from cellulose filters activate the cascade through the Factor G pathway, producing a positive unrelated to endotoxin unless a glucan-blocking buffer is used. A passing result is a narrow claim, not a general assertion of non-pyrogenicity.

A value quoted without the dilution factor and the interference control is uninterpretable, because an inhibited sample reads low and looks reassuring. The wider error is treating this number as the microbiological credential for an injectable. It says nothing about sterility, nothing about particulates, and nothing about what happened to the container after the sample was drawn.